CB 001 - Ceronco Biosciences

Drug Profile

CB 001 - Ceronco Biosciences

Alternative Names: CB-001 - Ceronco Biosciences; Doxorubicin liposomal - Ceronco Biosciences; GC enriched liposomal doxorubicin - Ceronco Biosciences; Glucosylceramide enriched doxorubicin - Ceronco Biosciences

Latest Information Update: 26 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ceronco Biosciences
  • Class Anthracyclines; Cytostatic antibiotics; Doxorubicins; Small molecules
  • Mechanism of Action Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Ovarian cancer; Soft tissue sarcoma

Most Recent Events

  • 26 Oct 2016 Preclinical trials in Ovarian cancer in Netherlands (unspecified route)
  • 26 Oct 2016 Preclinical trials in Soft tissue sarcoma in Netherlands (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top